Summit Therapeutics Inc.

NasdaqGM:SMMT

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 19.46 B

Share Price

USD 26.20

Avg Daily Volume

3,911,087

Change (1 day)

0.73%

Change (1 year)

93.79%

Change (YTD)

46.78%

Summit Therapeutics Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2023: -246,222.18%

Summit Therapeutics Inc. EBITDA Margin is -246,222.18% for the Trailing 12 Months (TTM) ending September 30, 2023, a 2,714.00% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Summit Therapeutics Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -8,749.90%, a 111.38% change year over year.
Summit Therapeutics Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -4,139.47%.
Summit Therapeutics Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending October 31, 2019 was -2,324.89%, a -33,945.55% change year over year.